enGene Therapeuti…
CACADenGene Therapeutics Inc. (US:ENGN) — Biotechnology: Biological Products (No Diagnostic Substances). Anzahl der Börsen, an denen die Aktien des Unternehmens gehandelt werden: 1. Auf dieser Seite: Kurs und Chart, Dividenden, größte Aktionäre und Entwicklung der Aktienanzahl.
Über das Unternehmen
- Website
- engene.com
- Sektor
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Hauptsitz
- SAINT-LAURENT, Canada
- CEO
- Mr. Ronald H. W. Cooper
- Mitarbeiter
- 81
- Ausstehende Aktien
- 67.02 Mio. Stand 2026-09-02
- Streubesitz
- 32.75 Mio.
- Marktkapitalisierung
- 132.02 Mio. USD
- Insider
- 0.11%
- Institutionelle Anleger
- 84.11%
- Branche (SIC)
- Biological Products, (No Diagnostic Substances)
Beschreibung
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
Börsen und Ticker
| Börse | Ticker | Währung | Preis | Typ |
|---|---|---|---|---|
| US USA Stocks | ENGN | USD | 1.8 -3.74% | Stammaktie |
Dividenden
Keine Dividendenzahlungen gefunden (geprüft 07.10.2026). Das Unternehmen schüttet wahrscheinlich keine Dividenden aus.
Neuigkeiten diese Woche
Noch keine Nachrichten von der Website des Unternehmens.
Größte Anteilseigner
| Inhaber | Anteil | Aktien | Berichtsdatum |
|---|---|---|---|
| FCPM III Services B.V. | 14.37% | 9.63 Mio. | 2026-06-30 |
| BML Capital Management,… | 9.95% | 6.67 Mio. | 2026-06-30 |
| Siren, L.L.C. | 9.34% | 6.26 Mio. | 2026-06-30 |
| Perceptive Advisors Llc | 7.2% | 4.82 Mio. | 2026-06-30 |
| Ameriprise Financial, In… | 3.99% | 2.68 Mio. | 2026-06-30 |
| Nextech Invest, Ltd. | 3.47% | 2.32 Mio. | 2026-06-30 |
| Adar1 Capital Management… | 3.14% | 2.1 Mio. | 2026-06-30 |
| Vestal Point Capital, LP | 2.49% | 1.67 Mio. | 2026-06-30 |
| Acorn Capital Advisors,… | 1.9% | 1.27 Mio. | 2026-06-30 |
| Peapod Lane Capital LLC | 1.64% | 1.1 Mio. | 2026-06-30 |
| Franklin Strategic Serie… | 0.73% | 486 579 | 2026-04-30 |
| Fidelity Concord Street… | 0.05% | 34 982 | 2026-07-31 |
| ETFis Series Trust I-Vir… | 0.05% | 32 625 | 2026-04-30 |
| TIFF INVESTMENT PROGRAM-… | 0.02% | 10 639 | 2026-06-30 |
| JNL Series Trust-JNL/DFA… | 0.01% | 9 974 | 2026-06-30 |
| Exchange Place Advisors… | 0.01% | 7 649 | 2026-06-30 |
| GROSSMAN WILLIAM (Office… | ≈0.01% | 5 102 | 2026-09-22 |
| Advanced Series Trust-AS… | 0% | 1 376 | 2026-06-30 |
| FORBION GROWTH OPPORTUNI… | — | — | 2024-10-30 |
